Denzil Douglas, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 501 Kings Hwy E Ste 109, Fairfield, CT 06825 Phone: 203-330-0248 |
News Archive
Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.
Approximately 500,000 Americans require dialysis to treat kidney disease; of that population nearly half of the deaths that occur are caused by cardiovascular disease. Dialysis patients are at elevated risk for sudden cardiac death, but physicians are unclear why these deaths occur because little research has been done to examine how to best manage heart disease in this high-risk population.
Patients who suffer from gingivitis are often advised to use disinfectant mouthwashes. In the future, the active ingredients in these products could be used in a completely different area: As scientists have reported in the journal Angewandte Chemie, Chlorhexidin and Alexidin increase programmed cell death and may be effective against cancers of the mouth and throat.
Health care stakeholders and lobbyists are increasingly convinced that CMS will not make the Jan. 1 deadline for launching the flagship accountable care organization program mandated by the Affordable Care Act as release of the final rule slips later into the fall.
› Verified 8 days ago